secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProPhase Labs, Inc. (PRPH)
CIK:        0000868278
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001641172-25-001488
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProPhase Labs reports FY2024 net loss of $53.4M; revenue down 81% to $6.8M
--------------------------------------------------------------------------

- Net revenue fell 80.6% to $6.8M from $35.0M, driven by near-zero COVID-19 testing volumes.
- Net loss widened to $53.4M ($2.61/share) vs $16.8M ($0.98/share) in FY2023; gross loss of $0.2M.
- Manufacturing division sold for ~$23M in Jan 2025; employee count reduced from 96 to 28.
- Cash and equivalents $0.7M at Dec 31, 2024, down from $1.6M; working capital deficit of $1.5M.
- Company plans cash-pay launch of BE-Smart esophageal test; evaluating sale of Nebula Genomics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/868278/000164117225001488/0001641172-25-001488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/868278/000164117225001488/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-001488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer